Aug 24 (Reuters) - Acrux Ltd ACR.AX :
* Acrux and Eli Lilly to appeal patent ruling on axiron ACR.AX
* Says "decision allows FDA-approved generic versions of axiron to enter the
U.S. marketplace "at risk," pending an appeal"
* Says Lilly and Acrux continue to believe that the axiron formulation and
axilla application patents are valid and enforceable
* Source text for Eikon ID:nASXsPkys